Zobrazeno 1 - 10
of 497
pro vyhledávání: '"Thomas, Dörner"'
Autor:
Marta Ferreira-Gomes, Yidan Chen, Pawel Durek, Hector Rincon-Arevalo, Frederik Heinrich, Laura Bauer, Franziska Szelinski, Gabriela Maria Guerra, Ana-Luisa Stefanski, Antonia Niedobitek, Annika Wiedemann, Marina Bondareva, Jacob Ritter, Katrin Lehmann, Sebastian Hardt, Christian Hipfl, Sascha Hein, Eberhard Hildt, Mareen Matz, Henrik E. Mei, Qingyu Cheng, Van Duc Dang, Mario Witkowski, Andreia C. Lino, Andrey Kruglov, Fritz Melchers, Carsten Perka, Eva V. Schrezenmeier, Andreas Hutloff, Andreas Radbruch, Thomas Dörner, Mir-Farzin Mashreghi
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Bone marrow plasma cells (BMPC) are the correlate of humoral immunity, consistently releasing antibodies into the bloodstream. It remains unclear if BMPC reflect different activation environments or maturation of their precursors. Here we de
Externí odkaz:
https://doaj.org/article/6afb3ecd327947ce81ffe2bed6522ae5
Autor:
Hector Rincon-Arevalo, Ana-Luisa Stefanski, Tuan Anh Le, Marcos Cases, Annika Wiedemann, Franziska Szelinski, Jacob Ritter, Van Duc Dang, Andreia C. Lino, Thomas Dörner, Eva Schrezenmeier
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Memory B cells (mBCs) are characterized by their long-term stability, fast reactivation, and capability to rapidly differentiate into antibody-secreting cells (ASCs). However, the role of T cells in the differentiation of mBCs, in contrast to naive B
Externí odkaz:
https://doaj.org/article/7a594cb5eb1e42ba98d13e234f77e8cc
Autor:
Gino Kwon, Annika Wiedemann, Lisa M. Steinheuer, Ana-Luisa Stefanski, Franziska Szelinski, Tomas Racek, Andreas Philipp Frei, Klas Hatje, Tony Kam-Thong, David Schubert, Thomas Schindler, Thomas Dörner, Kevin Thurley
Publikováno v:
npj Systems Biology and Applications, Vol 9, Iss 1, Pp 1-12 (2023)
Abstract Systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) share clinical as well as pathogenic similarities. Although previous studies suggest various abnormalities in different immune cell compartments, dedicated cell-type
Externí odkaz:
https://doaj.org/article/d842d9b1ede44c8c9b4c539caeb38071
Autor:
Richard Furie, Peter Nash, Amit Saxena, Thomas Dörner, Subhashis Banerjee, Joan Merrill, Marilyn Pike, Coburn Hobar, Samantha Pomponi, Ravi Koti, Thomas Wegman
Publikováno v:
Lupus Science and Medicine, Vol 11, Iss Suppl 1 (2024)
Externí odkaz:
https://doaj.org/article/faf247927fb4430283d6619bc5ef7574
Autor:
Thomas Dörner
Publikováno v:
Lupus Science and Medicine, Vol 10, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/78d11654ce84459d967e617a876b1cf0
Autor:
Daniel J. Wallace, Thomas Dörner, David S. Pisetsky, Jorge Sanchez‐Guerrero, Anand C. Patel, Dana Parsons‐Rich, Claire Le Bolay, Elise E. Drouin, Amy H. Kao, Hans Guehring, Maria Dall'Era
Publikováno v:
ACR Open Rheumatology, Vol 5, Iss 1, Pp 38-48 (2023)
Objective Evobrutinib is a highly selective, orally administered Bruton's tyrosine kinase (BTK) inhibitor. The objective of this phase II, multicenter, randomized, double‐blind, placebo‐controlled trial was to evaluate the efficacy and safety of
Externí odkaz:
https://doaj.org/article/fbfb7923863e4170999f2062f9b263dc
Autor:
Tuan Anh Le, Van Trung Chu, Andreia C. Lino, Eva Schrezenmeier, Christopher Kressler, Dania Hamo, Klaus Rajewsky, Thomas Dörner, Van Duc Dang
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 30, Iss , Pp 621-632 (2022)
Human B lymphocytes are attractive targets for immunotherapies in autoantibody-mediated diseases. Gene editing technologies could provide a powerful tool to determine gene regulatory networks regulating B cell differentiation into plasma cells, and i
Externí odkaz:
https://doaj.org/article/174f4a9188c14eeabc505f36d39a9a14
Autor:
Josef S Smolen, Yoshiya Tanaka, Michelle Petri, Inmaculada de la Torre, Thomas Dörner, Gabriella Meszaros, Hong Zhang, Maher Issa, Eric Morand, Christina Dickson, Maria Silk
Publikováno v:
RMD Open, Vol 9, Iss 3 (2023)
Objectives To assess the safety of the oral Janus kinase inhibitor baricitinib in adult patients with systemic lupus erythematosus (SLE) receiving stable background therapy. Topics of special interest included infections and cardiovascular and thromb
Externí odkaz:
https://doaj.org/article/b0fa1e1523c24778a50a0ff1915f0a24
Autor:
Tobias Alexander, Thomas Dörner, Franziska Szelinski, Andreia C Lino, Karin Reiter, Annika Wiedemann, Sebastian Fuchs, Ana-Luisa Stefanski, Eva Vanessa Schrezenmeier, Hector Rincon-arevalo, Jacob Ritter, Marie Lettau, Duc Van Dang, Andreas P Frei
Publikováno v:
Lupus Science and Medicine, Vol 10, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/0c4e5e03657d4a2ca9407037720619d6
Autor:
Thomas Dörner, Ronald F. van Vollenhoven, Andrea Doria, Bochao Jia, Jorge A. Ross Terres, Maria E. Silk, Stephanie de Bono, Peter Fischer, Daniel J. Wallace
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-9 (2022)
Abstract Background Patients with systemic lupus erythematosus (SLE) have substantial unmet medical need. Baricitinib is a Janus kinase (JAK)1 and 2 inhibitor that was shown to have therapeutic benefit in patients with SLE in a phase II clinical tria
Externí odkaz:
https://doaj.org/article/4d118c8e78e2474c874245f67f839d0d